(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.
Rallybio's earnings in 2025 is -$41,652,000.On average, 1 Wall Street analyst forecast RLYB's earnings for 2025 to be -$37,607,824, with the lowest RLYB earnings forecast at -$37,607,824, and the highest RLYB earnings forecast at -$37,607,824.
In 2026, RLYB is forecast to generate -$33,429,177 in earnings, with the lowest earnings forecast at -$33,429,177 and the highest earnings forecast at -$33,429,177.